Table 2.
Subgroups analysis in ALS patients.
| Subgroup analysis | Median survival (months) | 95% CI | IQR | P-value | ||
|---|---|---|---|---|---|---|
| Site of onset | Bulbar Spinal Bulbar Spinal Bulbar Spinal Bulbar Spinal |
Stage 1 Stage 2 Stage 3 Stage 4 |
10.13 12.17 7.13 7.50 6.13 7.00 4.17 4.48 |
9.10–11.23 11.13–13.20 6.02–9.00 7.07–8.13 5.10–7.00 6.07–7.13 3.53–5.10 4.07–5.07 |
5.03–18.50 6.10–22.28 4.00–12.17 4.03–13.20 3.01–9.17 4.00–11.17 2.27–7.00 2.26–7.13 |
0.038* 0.478 0.148 0.638 |
| Onset age | Young-onset >45 years Young-onset >45 years Young-onset >45 years Young-onset >45 years |
Stage 1 Stage 2 Stage 3 Stage 4 |
16.20 10.83 10.13 7.10 7.25 6.13 5.10 4.00 |
13.83–18.23 9.18–12.00 8.10–12.17 6.10–8.00 6.50–8.70 6.00–7.00 4.17–6.02 3.53–4.30 |
7.13–26.30 5.10–19.30 5.10–16.23 4.02–12.17 4.07–12.20 3.65–10.13 2.98–7.13 2.03–6.67 |
< 0.001* < 0.001* 0.002* 0.020* |
| Riluzole | Treated Untreated Treated Untreated Treated Untreated Treated Untreated |
Stage 1 Stage 2 Stage 3 Stage 4 |
13.10 11.13 8.13 7.13 7.07 6.13 4.10 4.57 |
11.13–15.25 10.13–12.17 7.13–10.35 6.13–8.10 6.03–8.10 6.03–7.08 4.00–5.00 4.07–5.10 |
6.10–24.22 5.10–19.30 4.08–14.52 4.00–12.17 3.98–12.17 4.00–10.10 2.23–7.13 2.30–7.06 |
0.026* 0.014* 0.158 0.924 |
| Riluzole treatment | Long-term Short-term Long-term Short-term Long-term Short-term Long-term Short-term |
Stage 1 Stage 2 Stage 3 Stage 4 |
15.47 11.05 10.57 7.07 7.13 6.80 4.50 4.07 |
12.20–20.00 7.13–13.20 8.00–12.17 6.05–9.13 5.10–9.55 5.10–8.10 3.53–6.00 3.07–5.07 |
8.10–26.30 5.10–19.30 5.10–16.26 4.00–12.20 4.00–12.60 3.73–11.13 2.27–7.13 2.10–7.13 |
0.009* 0.007* 0.265 0.890 |
| Long-term treatment | Early stage Late Stage Early stage Late Stage Early stage Late Stage Early stage Late Stage |
Stage 1 Stage 2 Stage 3 Stage 4 |
19.20 12.20 11.93 7.13 8.17 5.07 4.75 3.47 |
13.20–22.27 9.18–19.30 8.13–15.13 5.10–12.00 6.07–11.00 5.00–9.08 3.82–6.10 2.53–6.05 |
8.13–25.87 6.07–26.67 5.55–18.32 4.00–13.23 4.07–13.68 3.00–11.17 2.47–7.28 2.05–7.35 |
0.227 0.019* 0.107 0.657 |
| Short-term treatment | Early stage Late Stage Early stage Late Stage Early stage Late Stage Early stage Late Stage |
Stage 1 Stage 2 Stage 3 Stage 4 |
10.10 12.65 8.50 7.06 6.30 7.00 4.07 4.00 |
7.13–13.10 6.00–17.27 6.57–11.13 5.96–8.17 4.10–8.17 5.00–9.17 3.03–5.57 3.00–5.67 |
6.08–18.50 4.00–21.02 5.09–12.20 4.00–12.00 3.25–11.12 4.00–11.18 2.55–7.48 2.03–7.13 |
0.699 0.304 0.880 0.740 |
| PEG | Yes No |
Stage 4 | 13.20 4.07 |
9.10–16.20 4.00–4.50 |
8.30–16.30 2.07–6.60 |
< 0.001* |
| NIPPV | Yes No |
Stage 4 | 8.30 4.10 |
6.70–11.05 4.00–4.57 |
6.00–14.18 2.10–6.72 |
< 0.001* |
ALS, amyotrophic lateral sclerosis; CI, confidence interval; IQR, inter-quartile range; PEG, gastrostomy percutaneous endoscopy; NIPPV, non-invasive positive pressure ventilation.
*
P < 0.05.